Nov. 11 (UPI) — Pfizer and BioNTech introduced Wednesday they are going to provide 200 million doses of their COVID-19 vaccine, if it is finally authorised, to member states within the European Union.
The businesses mentioned the deal additionally offers the bloc an choice for an additional 100 million doses of their BNT162b2 vaccine, which is within the closing stage of human scientific trials and awaiting regulatory approvals.
“Right this moment’s finalized provide settlement with the European Fee represents the most important preliminary order of vaccine doses for Pfizer and BioNTech up to now and a significant step towards our shared aim of creating a COVID-19 vaccine out there to susceptible populations,” Pfizer Chairman and CEO Albert Bourla mentioned in a press release.
“That is probably the most promising vaccine to this point,” European Fee President Ursula von der Leyen added. “As soon as this vaccine turns into out there, our plan is to deploy it rapidly, in all places in Europe.”
The contract is the fourth to this point between the EU and pharmaceutical corporations creating doable vaccines. The alliance additionally has agreements with AstraZeneca, Sanofi-GSK and Johnson & Johnson and has explored comparable preparations with Moderna and CureVac.
“And extra will come, as a result of we have to have a broad portfolio of vaccines based mostly on completely different applied sciences,” von der Leyen added, noting that the EU has already begun working with member states to organize vaccination campaigns.
“We’re nearly there,” she mentioned.
Pfizer mentioned Monday that early knowledge from its final-stage trial, which gave two doses of the vaccine to human volunteers, signifies it’s efficient in about 90% of sufferers.
Those that developed safety from the coronavirus, it famous, did so about 28 days after the primary dose and per week after the second.